Parkinson's drug development through AI and massive compound screening

ZeClinics joins AseBio, Celtarys Research, and USC-Biofarma in a groundbreaking €147,000 project using AI and compound screening to develop new drugs for Parkinson's.

Start – End dates: 16/05/2023- 16/04/2024

Project reference: AEI-010500-2023-150

Total budget: 147,000€

Financed by: Spanish Ministry of Industry and Tourism, and the European Union


This project has received funding from the Spanish Ministry of Industry and Tourism within the support program for AEIs to contribute to the improvement of the competitiveness of the Spanish industry, with the support of the European Union through the Recovery, Transformation and Resilience Plan.


ASEBIO, Celtarys Research, Zeclinics y el grupo Biofarma de la Universidad de Santiago de Compostela.



Parkinson’s disease represents the second most common neurodegenerative disease in industrialized countries after Alzheimer’s disease. Its manifestation consists of symptoms related to the autonomic nervous system. Patients experience involuntary or uncontrollable movements, tremors, stiffness, and difficulty with balance and coordination.

To date, there are only drugs to alleviate symptoms once the disease is diagnosed, but there are no drugs that address the causes of the disease or help prevent it. In this context, this study framed within Line 3 of “Digital Technologies Projects” aims to identify new therapeutic molecules to treat Parkinson’s disease.

To achieve this goal, ZeClinics is committed to providing its expertise in target validation and in vivo drug screening, propelling the project forward. Partnering with Celtarys Research’s innovative approach to fluorescent tools and USC-Biofarma’s cutting-edge in vitro screening capabilities, our mission is to uncover new drugs for Parkinson’s and revolutionize collaborative drug discovery across various diseases.